A phase III, double-blind, placebo-controlled study of the efficacy, safety and tolerability of antegren (natalizumab) in maintaining clinical response and remission in Crohn's disease (ENACT-2). - Sandborn,W.; Colombel,JF.; Enns,R. (Gastroenterology, 2004)